{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:54:42Z","timestamp":1783036482783,"version":"3.54.6"},"reference-count":21,"publisher":"Japanese Society of Internal Medicine","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2019,3,1]]},"DOI":"10.2169\/internalmedicine.1613-18","type":"journal-article","created":{"date-parts":[[2018,10,16]],"date-time":"2018-10-16T18:30:34Z","timestamp":1539714634000},"page":"737-742","source":"Crossref","is-referenced-by-count":8,"title":["Rheumatoid Arthritis Complicated with Anti-melanoma Differentiation-associated Gene 5 Antibody-positive Interstitial Pneumonia"],"prefix":"10.2169","volume":"58","author":[{"given":"Haruki","family":"Matsumoto","sequence":"first","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuzo","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuya","family":"Fujita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makiko","family":"Yashiro-Furuya","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Matsuoka","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Asano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroko","family":"Kobayashi","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Watanabe","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Migita","sequence":"additional","affiliation":[{"name":"Department of Rheumatology, Fukushima Medical University School of Medicine, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Betteridge Z, McHugh N. Myositis-specific autoantibodies: an important tool to support diagnosis of myositis. J Intern Med 280: 8-23, 2016.","DOI":"10.1111\/joim.12451"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Koga T, Fujikawa K, Horai Y, et al. The diagnostic utility of anti-melanoma differentiation-associated gene 5 antibody testing for predicting the prognosis of Japanese patients with DM. Rheumatology (Oxford) 51: 1278-1284, 2012.","DOI":"10.1093\/rheumatology\/ker518"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Nakashima R, Imura Y, Kobayashi S, et al. The RIG-I-like receptor IFIH1\/MDA5 is a dermatomyositis-specific autoantigen identified by the anti-CADM-140 antibody. Rheumatology (Oxford) 49: 433-440, 2010.","DOI":"10.1093\/rheumatology\/kep375"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Sato S, Kuwana M, Fujita T, Suzuki Y. Anti-CADM-140\/MDA5 autoantibody titer correlates with disease activity and predicts disease outcome in patients with dermatomyositis and rapidly progressive interstitial lung disease. Mod Rheumatol 23: 496-502, 2013.","DOI":"10.3109\/s10165-012-0663-4"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Sato S, Hirakata M, Kuwana M, et al. Autoantibodies to a 140-kd polypeptide, CADM-140, in Japanese patients with clinically amyopathic dermatomyositis. Arthritis Rheum 52: 1571-1576, 2005.","DOI":"10.1002\/art.21023"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Sato S, Hoshino K, Satoh T, et al. RNA helicase encoded by melanoma differentiation-associated gene 5 is a major autoantigen in patients with clinically amyopathic dermatomyositis: association with rapidly progressive interstitial lung disease. Arthritis Rheum 60: 2193-2200, 2009.","DOI":"10.1002\/art.24621"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Sato S, Murakami A, Kuwajima A, et al. Clinical utility of an enzyme-linked immunosorbent assay for detecting anti-melanoma differentiation-associated gene 5 autoantibodies. PLoS One 11: e0154285, 2016.","DOI":"10.1371\/journal.pone.0154285"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Koga T, Kaieda S, Okamoto M, et al. Successful treatment of rapidly progressive unclassifiable idiopathic interstitial pneumonia with anti-melanoma differentiation-associated gene-5 antibody by intensive immunosuppressive therapy. Intern Med 57: 1039-1043, 2018.","DOI":"10.2169\/internalmedicine.9553-17"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Gonz\u00e1lez-Moreno J, Raya-Cruz M, Losada-Lopez I, Cacheda AP, Oliver C, Colom B. Rapidly progressive interstitial lung disease due to anti-MDA5 antibodies without skin involvement: a case report and literature review. Rheumatol Int 2018.","DOI":"10.1007\/s00296-018-3991-7"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Tanizawa K, Handa T, Nakashima R, et al. HRCT features of interstitial lung disease in dermatomyositis with anti-CADM-140 antibody. Respir Med 105: 1380-1387, 2011.","DOI":"10.1016\/j.rmed.2011.05.006"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Tsuchiya Y, Takayanagi N, Sugiura H, et al. Lung diseases directly associated with rheumatoid arthritis and their relationship to outcome. Eur Respir J 37: 1411-1417, 2011.","DOI":"10.1183\/09031936.00019210"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Sato Y, Otsuka K, Tamai K, Ono Y, Hamaguchi Y, Tomii K. An atypical clinical course of anti-mda5 antibody-positive interstitial lung disease in a patient with three deteriorations in 9 years. Intern Med 56: 341-346, 2017.","DOI":"10.2169\/internalmedicine.56.6856"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Suzuki A, Kondoh Y, Taniguchi H, et al. Lung histopathological pattern in a survivor with rapidly progressive interstitial lung disease and anti-melanoma differentiation-associated gene 5 antibody-positive clinically amyopathic dermatomyositis. Respir Med Case Rep 28: 5-8, 2016.","DOI":"10.1016\/j.rmcr.2016.05.008"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Kochi Y, Kamatani Y, Kondo Y, et al. Splicing variant of WDFY4 augments MDA5 signalling and the risk of clinically amyopathic dermatomyositis. Ann Rheum Dis 77: 602-611, 2018.","DOI":"10.1136\/annrheumdis-2017-212149"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Yang W, Shen N, Ye DQ, et al. Genome-wide association study in Asian populations identifies variants in ETS1 and WDFY4 associated with systemic lupus erythematosus. PLoS Genet 6: e1000841, 2010.","DOI":"10.1371\/journal.pgen.1000841"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Zhang Y, Bo L, Zhang H, Zhuang C, Liu R. E26 transformation-specific-1 (ETS1) and WDFY family member 4 (WDFY4) polymorphisms in Chinese patients with rheumatoid arthritis. Int J Mol Sci 15: 2712-2721, 2014.","DOI":"10.3390\/ijms15022712"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Hoa S, Troyanov Y, Fritzler MJ, et al. Describing and expanding the clinical phenotype of anti-MDA5-associated rapidly progressive interstitial lung disease: case series of nine Canadian patients and literature review. Scand J Rheumatol 47: 210-224, 2018.","DOI":"10.1080\/03009742.2017.1334814"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Moulis G, Sommet A, Lapeyre-Mestre M, Montastruc JL. Association Fran\u00e7aise des Centres R\u00e9gionaux de PharmacoVigilance. Is the risk of tumour necrosis factor inhibitor-induced lupus or lupus-like syndrome the same with monoclonal antibodies and soluble receptor? A case\/non-case study in a nationwide pharmacovigilance database. Rheumatology (Oxford) 53: 1864-1871, 2014.","DOI":"10.1093\/rheumatology\/keu214"},{"key":"19","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1177\/0961203314523871","volume":"23","author":"S Ara\u00fajo-Fern\u00e1ndez","year":"2014","unstructured":"19. Ara\u00fajo-Fern\u00e1ndez S, Ahij\u00f3n-Lana M, Isenberg DA. Drug-induced lupus: including anti-tumour necrosis factor and interferon induced. Lupus 23: 545-553, 2014.","journal-title":"Lupus","ISSN":"https:\/\/id.crossref.org\/issn\/0961-2033","issn-type":"print"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Cantaert T, Baeten D, Tak PP, van Baarsen LG. Type I IFN and TNF\u03b1 cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance. Arthritis Res Ther 12: 219, 2010.","DOI":"10.1186\/ar3150"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Horai Y, Koga T, Fujikawa K, et al. Serum interferon-\u03b1 is a useful biomarker in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive dermatomyositis. Mod Rheumatol 25: 85-89, 2015.","DOI":"10.3109\/14397595.2014.900843"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1613-18\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,10,26]],"date-time":"2019-10-26T19:05:22Z","timestamp":1572116722000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/58\/5\/58_1613-18\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,1]]},"references-count":21,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.1613-18","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,1]]}}}